Impact of anticoagulation prior to COVID-19 infection: a propensity score-matched cohort study

Blood. 2020 Jul 2;136(1):144-147. doi: 10.1182/blood.2020006941.

Abstract

Tremblay and colleagues asked whether patients receiving either routine anticoagulation or antiplatelet therapy for existing conditions prior to becoming ill with COVID-19 have different outcomes from patients receiving neither therapy. After matching for existing comorbidities, this retrospective observational study finds no evidence for an effect of prediagnosis anticoagulation on mortality.

Publication types

  • Letter

MeSH terms

  • Adult
  • Aged
  • Anticoagulants / therapeutic use*
  • Betacoronavirus / drug effects
  • COVID-19
  • Coronavirus Infections / drug therapy
  • Coronavirus Infections / epidemiology*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Pandemics
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Pneumonia, Viral / drug therapy
  • Pneumonia, Viral / epidemiology*
  • Propensity Score
  • Protective Agents / therapeutic use*
  • Protective Factors
  • Retrospective Studies
  • SARS-CoV-2
  • Survival Analysis

Substances

  • Anticoagulants
  • Platelet Aggregation Inhibitors
  • Protective Agents